arrow
E

Eric F. Morand

monash university
H指数:74
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anifrolumab Plus Standard of Care Reduces Long-Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real-World External Control Study

安尼福利单抗联合标准治疗方案可降低系统性红斑狼疮成年患者长期心血管损伤:一项真实世界外部对照研究的结果

2026-09-190
OAAI
Predictive correlates of arthritis and joint damage in systemic lupus erythematosus: a multinational prospective cohort study

系统性红斑狼疮中关节炎和关节损伤的预测性相关因素:一项多国前瞻性队列研究

2026-05-110
OA
Predictors of damage accrual by organ domain in systemic lupus erythematosus

系统性红斑狼疮中按器官领域累积损伤的预测因子

2025-12-010
OAAI
Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active
2025-12-010
OAAI
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus

两项随机、安慰剂对照、III期临床试验的设计:Deucravacitinib(一种口服、选择性、变构TYK2抑制剂)在系统性红斑狼疮中的应用

2025-09-080
PRE
ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations

ERN ReCONNET–SLICC–SLEuro专家共识:罕见系统性红斑狼疮表现的药物治疗管理

2025-05-230
PRE
Frequency and Determinants of Flare and Persistently Active Disease in a Large Multinational Prospective Lupus Cohort

系统性红斑狼疮大型跨国前瞻性队列中flare和持续性活动性疾病的频率与决定因素

2025-02-260
OAAI
Time trends of variability in disease activity in systemic lupus erythematosus
2025-02-120
OAAI
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)

中重度系统性红斑狼疮患者的真实治疗模式和临床特征: 对SLE前瞻性观察队列研究 (SPOCS) 的分析

2025-01-230
OAAI
Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus
2025-01-190
OAAI
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trialsI

LLDAS与安尼福卢单抗治疗系统性红斑狼疮患者中缓解的达成:来自TULIP和长期扩展随机对照试验的结果

2025-01-010
PRE